Ascendis Pharma A/S (NASDAQ:ASND) Receives $295.39 Average Target Price from Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus rating of “Buy” by the nineteen research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, sixteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $295.3889.

A number of analysts have recently weighed in on ASND shares. Wells Fargo & Company cut their target price on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $329.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Barclays upped their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Wedbush reiterated an “outperform” rating and set a $273.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th.

Insiders Place Their Bets

In other news, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were bought at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the transaction, the director owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 40.00% of the company’s stock.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of ASND. Perceptive Advisors LLC bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth $166,367,000. Wellington Management Group LLP lifted its position in shares of Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after buying an additional 880,836 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Ascendis Pharma A/S by 200.0% during the 3rd quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock worth $119,286,000 after buying an additional 400,000 shares during the last quarter. Spyglass Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth $77,267,000. Finally, Principal Financial Group Inc. lifted its position in shares of Ascendis Pharma A/S by 29.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock worth $218,871,000 after buying an additional 232,730 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $228.00 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The stock’s fifty day moving average price is $232.04 and its two-hundred day moving average price is $224.54. Ascendis Pharma A/S has a one year low of $160.86 and a one year high of $250.74. The firm has a market cap of $14.22 billion, a price-to-earnings ratio of 26.30 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. On average, equities analysts forecast that Ascendis Pharma A/S will post 4.55 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.